SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-20-120981
Filing Date
2020-04-27
Accepted
2020-04-27 16:20:41
Documents
11
Effectiveness Date
2020-04-27

Document Format Files

Seq Description Document Type Size
1 DEFA14A d900277ddefa14a.htm DEFA14A 30983
2 GRAPHIC g900277a3.jpg GRAPHIC 4185
3 GRAPHIC g900277b1.jpg GRAPHIC 4204
4 GRAPHIC g900277b2.jpg GRAPHIC 809
5 GRAPHIC g900277b3.jpg GRAPHIC 4301
6 GRAPHIC g900277b4.jpg GRAPHIC 857
7 GRAPHIC g900277b5.jpg GRAPHIC 686
8 GRAPHIC g900277b6.jpg GRAPHIC 3917
9 GRAPHIC g900277gra001.jpg GRAPHIC 9247
10 GRAPHIC g900277gra002.jpg GRAPHIC 9430
11 GRAPHIC g900277snap0003_1.jpg GRAPHIC 2214
  Complete submission text file 0001193125-20-120981.txt   77545
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

IRS No.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35703 | Film No.: 20820274
SIC: 2834 Pharmaceutical Preparations